Ausgewählte Vorträge
2014-2010
2014
International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
17th Annual European Congress, Amsterdam / Niederlande, 08.-12. November 2014:
The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs).
(Plenarvortrag)
Abstract publiziert in Value in Health 17 (7), 2014: A324.
- Präsentation (197,9 KiB)
- Abstract (94,4 KiB)
Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases in Europe.
(Poster-Präsentation)
Abstract publiziert in Value in Health 17 (7), 2014: A525.
- Poster (606,2 KiB)
- Abstract (92,6 KiB)
Swiss Medical Board (SMB)
Oktober / November 2014:
Pro Bono Beitrag zur weiteren Konzeptentwicklung der SwissHTA Konvergenzinitiative und des Swiss Medical Board (SMB)
HTA & Stakeholder Involvement – International References.
(Eingeladener Vortrag, Bern / Schweiz, 19. November 2014)
- Download (398,5 KiB)
HTA & Topic Selection / Scoping – International References.
(Eingeladener Vortrag, Bern / Schweiz, 07. Oktober 2014)
- Download (909,8 KiB)
“Warum das Swiss Medical Board nicht genügt.”
- Download (570,5 KiB)
Rare Diseases and Orphan Drug Symposium and Orphan Drug Regulation Workshop
[Ilac Bilincini Gelistirme ve Akilci Ilac Dernegi]
Antalya / Türkei, 13.(/14.) September 2014:
Interventions for Rare / Ultra-Rare Disorders and the Logic of Cost Effectiveness.
(Eingeladener Vortrag)
- Download (651,5 KiB)
11th Annual HTAi Meeting 2014
Grand Hyatt Washington, Washington, DC / USA, June 14-18, 2014:
Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?
(Vortrag, Veranstaltung zu “Valuing Health – Past, Present, and Future”, Washington, DC, 16. Juni 2014)
Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus.
(Vortrag, Veranstaltung zu “How to Improve Resource Allocation”, Washington, DC, 16. Juni 2014)
2013
International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
16th Annual European Congress , Dublin / Irland, 02.-06. November 2013:
The Measurement of Health-Related Quality of Life: First German Findings from the Multi-Instrument Comparison (MIC) Study.
Value in Health 16 [7] (2013) A330.
European Society for Child and Adolescent Psychiatry (ESCAP)
15th International ESCAP Congress
Dublin / Irland, 06.-10. Juli 2013:
Attention-Deficit/Hyperactivity Disorder (ADHD):
A Longitudinal Analysis (2003-2009) of Prevalence, Health Care, and Direct Cost based upon Administrative Data from Nordbaden / Germany.
(Symposium)
- Download (2,8 MiB)
4th World Congress on Attention-Deficit/Hyperactivity Disorder (ADHD) - From Childhood to Adult Disease
Mailand, Italien, 07. Juni 2013:
The Costs and Benefits of Attention-Deficit/Hyperactivity Disorder - An Economic View.
(Eingeladener Plenumsvortrag)
Abstract publiziert in Attention-Deficit/Hyperactivity Disorders [ADHD] Vol. 5 (2), 2013: 113.
- Präsentation (573,9 KiB)
- Abstract (227,4 KiB)
European Pricing Platform (EPP)
3rd EPP Life Sciences Forum, Montreux, Schweiz, 05. Juni 2013:
Europe - Problem Child or Rising Star? Outlook and Opportunities for Growth.
(Eingeladener Plenarvortrag)
2012
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
15th Annual European Congress, Berlin, Deutschland, 03.-07. November 2012:
Wissenschaftlicher Programmvorsitz - Interview zu Kongresshighlights
The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles.
(Abstract) Value in Health 15 (7), 2012: A319.
- Download (877,3 KiB)
Involvement of CNS Specialists in Health Care Provision for Patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
(Abstract) Value in Health 15 (7), 2012: A344.
- Download (166,2 KiB)
Health Care Utilization Research in Germany: Characterization of the Nordbaden Database.
(Abstract) Value in Health 15 (7), 2012: A303.
- Download (266,5 KiB)
9th European Conference on Health Economics (ECHE)
Zürich, Schweiz, 18.-21. Juli 2012:
Will Progress in Applied Health Economics Depend on a New Evaluation Paradigm?
- Download (315,5 KiB)
12th International Symposium on MPS and Related Diseases
Amsterdam (Noordwijkerhout), Niederlande, 30. Juni 2012:
Cost Effectiveness and Orphan Drugs.
(Eingeladener Plenumsvortrag)
Interview zu Noordwijkerhout Symposium
2011
International Society for Pharmacoeconomics and Outcomes Research (ISPOR),
14th Annual European Congress, Madrid, Spanien, 05.-08. November 2011:
Increasing Use of Medication for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Germany Between 2003 and 2009.
(Abstract) Value in Health 14 (7) 2011: A300.
- Download (214,2 KiB)
The Cost Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder in Adult Patients.
(Abstract) Value in Health14 (7) 2011: A403.
- Download (212,3 KiB)
UK Adult ADHD Network (UKAAN), First European Adult ADHD Conference
Savoy Place, London, England, 23. September 2011:
ADHD across the lifespan – what are the costs to society?
- Download (1,2 MiB)
Verein für Socialpolitik, Ausschuss für Gesundheitsökonomie
Augsburg, Deutschland, 16. Oktober 2010:
Michael Schlander, Munir Khan, John McKie, and Jeff Richardson:
Health-Realted Quality of Life (HRQoL) Instruments: Some Prerequisites for Their Appropriate Use in Economic Evaluation.